Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Indication name: Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a life-threatening condition when the first-line treatment for acute graft-versus-host disease (aGVHD), systemic corticosteroids, does not work. aGVHD is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT), occurring in 30-50% of patients. It is caused by the donor's immune cells attacking the recipient's tissues. The incidence and severity of aGVHD are influenced by various risk factors. It tends to occur more frequently and with greater severity in cases of alloHCT from HLA-nonidentical or unrelated donors compared to HLA-matched sibling donors. Additional non-HLA risk factors associated with aGVHD encompass older patient or donor age, the utilization of a female donor for a male recipient, the use of peripheral blood as the source of stem cells, the choice of GVHD prophylaxis, and the recipient's seropositivity for cytomegalovirus. The European Society for Blood and Marrow Transplantation (EBMT) – European Leukemia Net (ELN) consensus working group has generated recommendations on treating aGvHD. In around one-third of cases, the disease is not improved after 4 weeks of treatment. Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) presents a significant challenge to healthcare providers caring for patients post-allogeneic hematopoietic cell transplantation. Extracorporeal photopheresis (ECP) and anti-thymocyte globulin (ATG) are commonly employed in treating SR-GvHD, with ECP demonstrating particular effectiveness in cases involving the skin, liver, and gut. However, there is no universally accepted standard of care for SR-aGVHD. Patients with steroid-resistant acute graft-versus-host disease (aGVHD) face a grim prognosis, with mortality rates exceeding 90%.

Thelansis’s “Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more